BigClassActions.com
Advertisement

Wyeth, Inc WYE Securities Stock Fraud

- by

Company: Wyeth, Inc
Ticker Symbol: WYE
Class Period: May-21-07 to Jul-29-08
Date Filed: Jun-18-10
Lead Plaintiff Deadline: Aug-17-10
Court: District of New Jersey
Allegations:
Roseland, NJ: A securities class action lawsuit was filed on June 18, 2010 in the United States District Court for the District of New Jersey, case number 2:10-cv-03105-SDW -MCA, on behalf of purchasers of Wyeth, Inc. ("Wyeth") common stock during the period between May 21, 2007 and July 29, 2008, inclusive (the "Class Period").

This action seeks damages for violations of Sections 10(b), 20(a), and 20A of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The defendants are Pfizer, Inc. ("Pfizer"), as successor-in-interest to Wyeth (now a wholly-owned operating subsidiary of Pfizer), Robert Essner (former Chairman and CEO of Wyeth), Bernard Poussot (former Chairman and CEO of Wyeth), Kenneth J. Martin (former CFO and Vice Chairman of Wyeth), Greg Norden (former CFO of Wyeth) and Robert R. Ruffolo, Jr. (former President, Wyeth Research and Senior Vice President, Wyeth) (collectively, "Defendants"). Prior to its acquisition by Pfizer, Wyeth was one of the world's largest pharmaceutical manufacturers. This action alleges that Defendants concealed material information and made false and misleading statements relating to one of its drugs under development.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Wyeth, Inc WYE Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Wyeth, Inc securities class action lawsuit. Please fill in our form on the right to submit your complaint for a free evaluation.

Maybe it's your stockbroker

Add Your Comment on This Issue

Please read our comment guidelines before posting.


Note: Your name will be published with your comment.


Your email will only be used if a response is needed.

Request Legal Help